on GENFIT (EPA:GNFT)
GENFIT to Showcase ACLF Research at EASL Congress 2025
GENFIT, a biopharmaceutical company focused on liver diseases, is set to present its latest research on Acute-on-Chronic Liver Failure (ACLF) at the European Association for the Study of the Liver (EASL) Annual Congress 2025. The event will feature six posters about ACLF and various sessions emphasizing its significance in hepatology.
The posters include studies on investigational treatments like VS-01 for patients with liver cirrhosis and a dual inhibitor targeting the NLRP3 inflammasome. Additionally, GENFIT will highlight the role of machine learning in identifying at-risk ACLF subpopulations.
GENFIT's participation extends beyond poster presentations, with involvement in EASL Studio sessions and collaborations with the European Foundation for the Study of Chronic Liver Failure. These engagements aim to advance discussions on patient care and innovative treatment strategies for ACLF.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news